High Dose Steroids in Children With Stroke

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age6-17
SponsorInsel Gruppe AG, University Hospital Bern

About this trial

This clinical trial deals with focal cerebral arteriopathy and childhood stroke, a rare but devastating condition.

Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection and there is increasing evidence that inflammatory processes play a crucial role in childhood stroke, influencing the outcome of the disease.

Analysis of existing data suggests that outcomes are improved and that there is less stroke recurrence in children treated with steroids to reduce the acute inflammatory processes. This clinical trial will be conducted in over 20 hospitals in several countries in order to investigate this.

Participants will be randomly separated into two groups. The first group will be treated with standard of care (including aspirin) combined with high dose steroids. The second group will be treated with standard of care (including aspirin) but without steroid treatment.

The objective is to investigate if children treated with a combination of high dose steroid and aspirin will have a better and quicker recovery of FCA, better clinical functional outcome, and less recurrence compared to children treated with aspirin alone.

This project has been identified by international pediatric stroke experts as the most important topic for a clinical trial in the field and is as well one of the most important research priorities identified by parents. The study results will also provide insight into the evolution of inflammatory vessel disease.

Eligibility criteria

Qualifiers

Informed consent of the legal representative of the trial participant documented by signature

Age > 6 months & < 18 years at time of stroke

Randomisation possible within 48 hours of diagnosis and maximum 96 hours after stroke onset

Newly acquired neurologic deficits

Disqualifiers

Previous stroke

Known syndromal disorders, as e.g. Trisomy 21, Neurofibromatosis type 1

Known genetic vasculopathies as e.g. posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies and eye anomalies syndrome (PHACES), actin alpha 2 (ACTA II)

Moyamoya or sickle cell disease

Trial design

Treatments tested in this trial

  • Methylprednisolone
  • Prednisolone

Treatment groups

70 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Insel Gruppe AG, University Hospital Bern

Lead sponsor

University of Bern

Collaborator

LUMIS International GmbH

Collaborator